Form 4: Recursion Pharmaceuticals CFO Michael Secora Executes Stock Option Plan, Sells Shares
SEC Form 4
Chief Financial Officer of Recursion Pharmaceuticals, Michael Secora, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.
Summary
- Michael Secora, the CFO of Recursion Pharmaceuticals, executed transactions involving Class A Common Stock on August 13 and 14, 2024.
- These transactions involved the exercise of stock options at a price of $2.22 and the subsequent sale of shares at weighted average prices of $6.3455 and $6.3501.
- The sales were conducted under a 10b5-1 trading plan adopted on March 1, 2024.
- On August 13, 2024, Secora acquired 39,375 shares through option exercise and sold 15,000 shares.
- On August 14, 2024, Secora acquired another 39,375 shares through option exercise and sold another 15,000 shares.
- Following these transactions, Secora directly owns 1,365,343 shares of Class A Common Stock.
- Secora also holds various stock options with exercise prices ranging from $2.22 to $11.40 and expiration dates extending to 2034.
- The reporting person has undertaken to provide full information regarding the number of shares sold at each separate sale price upon request.
Sentiment
Score: 5
Explanation: Neutral sentiment as the transactions are part of a pre-planned trading strategy. The CFO is exercising options and selling shares, which is not inherently positive or negative.
Positives
- The transactions are being conducted under a pre-arranged 10b5-1 trading plan, which can reassure investors that the sales are not based on insider information.
Negatives
- The sale of shares by the CFO could be perceived negatively by some investors, although it is part of a pre-arranged plan.
Risks
- Continued sales of shares by insiders could put downward pressure on the stock price.
- The market's reaction to insider sales can be unpredictable and may impact investor sentiment.
Industry Context
Insider trading activity is common in publicly traded companies, and the use of 10b5-1 plans is a standard practice to allow insiders to sell shares without being accused of trading on non-public information. Investors often monitor such filings to gauge executive sentiment and potential future stock performance.
Comparison to Industry Standards
- Comparing Recursion Pharmaceuticals' insider trading activity to similar biotech companies like Exscientia or Schrödinger would provide context.
- Examining the frequency and size of insider transactions in these companies can help determine if Recursion's activity is typical.
- Benchmarking the stock performance following similar insider sales in comparable companies could offer insights.
Stakeholder Impact
- Shareholders may react to the news of insider sales, potentially impacting the stock price.
- Employees may be indirectly affected by any changes in stock price or investor sentiment.
Key Dates
| Date | Description |
|---|---|
| 2020-03-01 | Option vests as to one forty-eighth (1/48th) of the shares subject to the award one month after March 1, 2020, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter. |
| 2022-02-04 | Stock Option (Right to Buy) $ 11.4 |
| 2022-03-01 | The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. |
| 2023-03-01 | The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. |
| 2024-03-01 | Reporting Person adopted a 10b5-1 trading plan. |
| 2024-03-01 | The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. |
| 2024-08-13 | CFO exercised stock options and sold shares. |
| 2024-08-14 | CFO exercised stock options and sold shares. |
| 2030-03-03 | Expiration date for some stock options. |
| 2032-02-04 | Expiration date for some stock options. |
| 2033-02-01 | Expiration date for some stock options. |
| 2034-02-09 | Expiration date for some stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.